Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ: ALNY )

246.27 -2.89 (-1.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all... 
Via Benzinga
Alnylam Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
3 Growth Stocks That Could Rocket Higher in 2023
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Via Benzinga
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter. 
Via Benzinga
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program
Via Benzinga
Alnylam Pharmaceuticals: Q3 Earnings Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
Where Alnylam Pharmaceuticals Stands With Analysts
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company
  
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Bear market, shmear market. These biotech stocks are soaring despite the market downturn. 
Via The Motley Fool
Where Alnylam Pharmaceuticals Stands With Analysts
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.